Han, Kelong <br/><br/>
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.  [electronic resource] 

 -  The AAPS journal  Sep 2014 
 - 1056-63 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1550-7416 
<br/><br/><label>Standard No.: </label>10.1208/s12248-014-9631-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--blood<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--blood<br/>Bayes Theorem<br/>Bevacizumab<br/>Biological Availability<br/>Capecitabine<br/>Cisplatin--administration & dosage<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Drug Monitoring<br/>Female<br/>Fluorouracil--administration & dosage<br/>Gastrectomy<br/>Humans<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Models, Biological<br/>Stomach Neoplasms--blood<br/>Treatment Outcome